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Abstract Reviews are an essential component of modern medicine.The volume of literature is large, even about a
singletreatmentforpulmonarydisease.Thetaskofretrievingalltherelevantpapers, then assessing the evidencetoreach
a valid conclusion is very time consuming.Atevery stage there is the riskof sampling error (failure to get all the evidence)
and bias (a systematic distortion of the results due to aweakness in themethodology).There are essentially twotypes of
review: narrative reviews that follow no rules, exposing them to sampling error and bias; and systematic reviews that
attempt to minimise these effects by following an explicit structure for retrieving all of the evidence and attempting an
objective synthesis of the results from the different trials. A good review can serve a number of purposes including: as-
sembling all the relevant evidence in one place, providing a valid estimate of the overall effect of treatment, producing
guidance for clinical practice and generating hypotheses for further trials about patients or settings in which the treat-
menteffectmaybe less ormore effective.r2002 Publishedby Elsevier Science Ltd.
Available online athttp://www.sciencedirect.comINTRODUCTION
This journal has created a new section that will contain
reviews and overviews of topics in respiratorymedicine,
usually but not exclusively concerning treatment. This
paper is designed to serve as an introduction and
guide.
Reviews of treatment are needed. Most of us scarcely
have time to read the last sentence of the conclusion in
the abstract of a paper, never mind critically appraise its
content.There is a large andever-growing literature con-
cerning therapy for pulmonary disease.There is usually a
number of relevant studies for a single treatment and it is
not possible for an individual clinician to keep upwith all
developments.Not only is the volume of publishedwork
large, it is also complex.Clinical trials have di¡erent de-
signs, inclusion and exclusion criteria and oftenuse di¡er-
ent measures of treatment e⁄cacy. Readers of papers
that describe clinical trials require not only the time to
devote to the enterprise, but also the appropriate criti-
cal appraisal skills needed to assess with con¢dence the
quality of the data presented, the strength of the evi-Correspondence should be addressed to Dr. P.W. Jones,Division of
Physiological Medicine, St George’s Hospital Medical School,Cramer
Terrace, London SW17ORE,UK.Fax +44 20 8725 5955,
E-mail: pjones@sghms.ac.ukdence and the validity of the conclusions drawn by the
paper’s authors.
Even the task of ¢nding the relevant papers is not as
simple as it ¢rst appears.We are all familiar withcarrying
out electronic searches for papers either byourselves or
with the help of amedical librarian, andwe all knowhow
over-inclusive such searches can be. Put they often turn
up some papers that we need andmany that we do not.
To make life easier, we are often tempted to limit our
searches using all sorts of devicesFsearching only the
last 2 years, only English languagepapers, etc.Oneuseful
device for restricting the search is use of the ‘AND’ op-
erator in the search term.This can increase the speci¢-
city of the search but has the potential to sacri¢ce
sensitivity for speci¢city, so must be used with care.
Having found all the potentially relevant papers it is
then necessary to screen out those that are not
appropriate. Not all papers that we want will be
readily available in the local library or electronically and
may be quite expensive to obtain through inter-library
loan services, so one only reads those that are most
accessible.
Having obtained the papers and found time to
read them, it will be necessary to synthesise all that
knowledge into an assessment of the value of the treat-
ment. That may be easier said than done. Clinical trials
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take into consideration, di¡erent pieces of information
that suggest ‘‘On the onehand thisyyandon the other
thatyy.’’. Itmayoftenbenecessary to tabulate ¢ndings
from thevarious papers to enable a reasonable overview
of the results from the di¡erent studies.Quite clearly, if a
clinician is interested in getting a balance view of the
overall e⁄cacy of even a single treatment, this will in-
volve a lot of work. As a result, in a busy world, most
clinicians’ considerations of a treatment’s e⁄cacy will be
based on a review of some form.
SAMPLINGERRORSANDBIAS
All scienti¢c assessments are prone to sampling error
and biases that may result in an incorrect conclusion.
Reading (reviewing) the literature is subject to these fac-
tors in the same way as the measurement of the basic
observations upon which the publications are based.
Sampling errors may be random, often due to an inade-
quate number of observations beingmade, or in the case
of reviews, papers that are read.These errors may also
be non-random, in which case the term ‘bias’ is used. Is-
sues concerningbiaswill appear recurrently in this paper.
Bias is de¢ned along these lines: ‘a systematic distortion
of a statistical result due to a variable that has not been
considered or accounted for in its derivation’. In the con-
text of obtaining results from clinical trials, there are
many potential sources of bias, apart from sampling er-
ror due to attempts to reduce the work of reviewing a
topic to a manageable load.
Systematic biases include publication bias. A
well-known example being trials with negative results
that are being published in abstract form only or in
non-English language journals (1, 2). A large study of
which I was a principal investigator was almost rejected
by a reviewer for a major respiratory journal because itTABLE 1. Some ofthe variations thatcan occur betweentrials o
Factor Variations
Dose Low, medium, high
Objective Many, eg: symptomrelief, prevention
Purpose oftrial Superiorityorequivalence
Delivery system Oral, metered dose inhaler, drypow
Age of patients Children or adults
Disease severity Mild, moderate, severe
Disease setting Acute, chronic stable
Trial design Randomised orcross-over
Comparator Usual care (placebo), di¡erentdose
Setting Community, hospital ambulatorycar
Trial duration HoursFyears
Outcome Manydi¡erentoutcomesFmaydepshowed that the treatment was only modestly e¡ective
Fso was judged to be ‘uninteresting’. Journals need high
citation ratingsFnegative results are cited less often
than positive ones. Other biases may creep in with the
construction of the search routine and most especially
with retrieval. For example, pharmaceutical companies
can often supply to clinicians reprints of studies that re-
port favourably upon their product, negative trails are
not so easy to come by.Within the Cochrane Airways
Group, sta¡ at the Editorial Base of the Airways Review
Group spend a long time at the British Library chasing
down clinical trials published in many di¡erent journals
that are not available, even in a large medical school li-
brary.
AVOIDINGBIAS INREVIEWS
It is clear from the foregoing that, to obtain the least-
biased estimate of the e⁄cacy of a treatment, a review
must be created using a very systematic approach. This
requires a set of rules that are similar, in many respects,
to thoseused for randomisedcontrolledclinical trials (3).
Reviews that follow this structured approach are
termed Systematic Reviews. This term is not synon-
ymous with the term ‘meta-analysis’ which is a group of
speci¢c statistical techniques used to aggregate results
fromdi¡erent trials.Whilst itmay notbe possible always
to aggregate results using statistics, this does not negate
the use of a systematic approach for the rest of the re-
view process. The alternative to a systematic review is
the so-called ‘Narrative Review’. Such reviews are more
common than Systematic Reviews, since they do not
have to use a rigorous and time-consumingmethodology.
However, they are open to many potential sources of
bias and may reach erroneous conclusions, not only
because they may not have identi¢ed all of the relevant
trials, but also because of a £awed analysis of the trialsf one class of drug
of exacerbations, disease progression, corticosteroid sparing
der inhaler, nebuliser
of drug, di¡erentdrug
e, emergencyroom, inpatient
end on objective
TABLE 2. The basic components of a systematic review
KDe¢ne the questionto be addressed
KObtain all the randomised controlled trial data
KUse explicit inclusion and exclusion criteria
K Extractdata carefully (obtainingdata from1y authors)
K Identify subgroups a priori
KAssemble all the data
KAggregate the data usingmeta-analysis (if possible)
K Test forheterogeneity (ie di¡erencesbetweentrials)
KDraw valid conclusions
KDistinguish between
No evidence of e¡ect
Evidence of no e¡ect
SYSTEMATICREVIEWS INRESPIRATORYMEDICINE 99that were retrieved. The following sections describe
some of the types of bias that may occur in any review,
whether systematic or narrative, but are more likely to
occur with the latter.
WHICHTYPEOF TRIALTOINCLUDE
INAREVIEW ?
The randomised controlled double-blind trial (RCT) de-
sign forms the cornerstone of the evaluation of treat-
ment e¡ects in lung disease. The reasons for this are
very simple. New treatments must be compared with
another treatment to know whether it has any bene¢-
cial e¡ect. The baseline state can be used for this pur-
pose, but this is fraught with problems. Not least is the
‘study e¡ect’, in which patients included in a clinical trial
improve spontaneously.This is not a ‘placebo’ e¡ect, it is
due to patient factors such as improved adherence or use
of usual therapy, andphysician factors such asbetter clin-
ical supervision and faster response to changes in state.
Thus, it is necessary to have a contemporaneous control
groupwho have‘usual care’or another comparator treat-
ment. Randomisation is used in an attempt to ensure
that the two treatment groups are matched at baseline.
There are always di¡erencesbetweenpatients and usual-
ly themost secureway of ensuring that each limb of the
studycontains patientswith same characteristics is to al-
locate them randomly.The success of this will depend on
chance and the size of the study.The bigger the patient
population, the lower the chance of random sampling
errors.
The third factor in the RCT is the double-blind com-
ponent.This is needed to ensure that neither patient not
trialist knows which treatment is being given.The ethics
behind this are that at the outset of the study the trialist
should be in ‘equipoise’Fi.e. they do not know which
limb of the study will have the better outcome. There
are too many important issues around this to be dis-
cussedhere, apart from the fact that if the trial is ethical,
then it is probablyunethicalnot to conceal the treatment
allocation. The reason being that the study’s purpose is
to produce the most reliable estimate of the e⁄cacy of
the treatment under test. There is good evidence that
lack of treatment allocation can lead to a large over-esti-
mate of the treatment’s e⁄cacy. The causes of this are
multi-factorial, but include treatment bias in which the
clinician and patient make other treatment decisions in
the knowledge of which trial therapy they are receiving,
and bias in themeasurement of treatment outcome.
The RCTshould not be thought of as being the ‘best’
trial, but rather the trial design inwhich biases aremini-
mised to the greatest degree. Clearly not all of the re-
quirements are achievable in all trials. For example,
sham lung-reduction surgery (thoracotomy with no sur-
gery to the lungs) is notpossible; nor is itpossible to pre-vent a patient knowing that they have received physical
rehabilitation for COPD, but this should not prevent the
use of design that will minimise identi¢able sources of
bias. It is for reasons of minimising bias, the Cochrane
Collaboration has focussed its e¡orts upon reviewing
RCTs or at the least trials that are adequately controlled.
ASKINGTHERIGHTQUESTIONIN
THEREVIEW
The ¢rst headings inTable 2 is: ‘De¢ne the question’.This
is the startingpoint for the review (4). In fact, this breaks
down into three components:
Which treatment is being assessed ?
Inwhom ?
Inwhat setting ?
It may seem surprising that it is necessary to specify
the treatment, since that ought to be apparent from the
title. However, take for example a narrative review en-
titled ‘‘Beta-adrenergic bronchodilators’’ (5). This could
include short- and long-acting drugs, acute or stable
chronic asthma, and several di¡erentmodes of drug de-
livery. Contrast this with ‘‘Nebulised beta2-agonists for
the treatment of acute asthma in the emergency depart-
ment’’ (6).Note that this title speci¢es the reason for the
treatment being given and the setting. The latter is im-
portant. There is still no agreed method of assessing
the severity of acute asthma, but on examining trials in
acute severe asthma, clear di¡erences in admission rate
are apparent between studies of patients reported to
have severe acute asthma.Thus, it is important to specify
whether the review covers treatment for acute asthma
in primary care, the emergency room or in patients ad-
mitted to hospital.
The question ‘‘In whom ?’’ addresses the inclusion and
exclusion criteria for the review.This de¢nes the limits of
generalisability of the conclusions drawn from the
review. For example, the NHLBI/WHO Global Initiative
on Obstructive Lung Disease (GOLD) de¢nes COPD as
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
∆ 
FE
V 
(lit
re)
Scatter
Plot
Mean
± SD
Mean
± SE
Box
Plot
90th
75th
50th
25th
10th
Mean
95% CI
FIG. 1. Changesin FEV1followingsalmeterolinCOPD.The scat-
ter plot shows all the individual data. SD: standard deviation; SE:
standard error; 95% CI: 95% con¢dence intervals; Box plot
shows the10th, 25th, 50th,75th and 90th centiles ofthe data.
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fully reversible (7). A degree of reversibility is usually
present, however, and some patients with COPD have a
clearly reversible element to their condition. This inter-
national de¢nition of COPD is relatively new, but some
trialists and authors of reviews use a tighter criterion
for the de¢nition, one that speci¢es that the patient’s
FEV1 should not reverse more than a certain amount.
Results from studies/reviews with such criteria may not
be generalisable to COPD patients identi¢ed using a
broader de¢nition.
SELECTINGTHEPRIMARYMEASURE
OF TREATMENTEFFECTIVENESS
In a clinical trial carried out to provide evidence for the
registration of a newdrug, the regulatory authorities re-
quire the trialists to specify their primary endpoint, i.e.
the outcome onwhich they are going to base their claim
for the e⁄cacy of the drug. The reason for this is that
there are many well-established measures of treatment
outcome andmost clinical trials incorporate a number of
these. The disadvantage is that, by random chance, one
or more of these will show an e¡ect in favour of one or
other treatment, so it is necessary to specify the pri-
mary outcome.
The same discipline should apply to reviews, since the
reviewer will have a large number of possible outcomes
to choose fromFwell over 20 in some cases. There is
currently no agreement as to which is the most impor-
tant outcome in each of the major respiratory diseases.
Furthermore, there are di¡erent treatment objectives
for each disease.For example, in COPD these include re-
lief of symptoms, reduction inmortality and slowing dis-
ease progression. Thus, the outcome should match the
purpose of the studyFwhichmeans that to three com-
ponent question listed above (Which treatment, in
Whom and Where ?) should be added ‘‘To what end or
Why ?’’
THE ‘AVERAGE’RESULT
Clinical trials are carried out in groups of patients re-
cruited because they are believed to be representative
of the population for whom the treatment is intended.
However, the trial population is not homogenous, it will
include patients with di¡erent levels of disease severity.
Furthermorewithin the population, theremay be di¡er-
ent (as yet unidenti¢ed) genetic factors that will in£u-
ence the response to therapy. Results of the trial are
given as a mean together with a measure of the distribu-
tion around thatmean (a standard error, standard devia-
tion or con¢dence intervals). But who remembers the
distribution statistic? Only the mean result is recalled
and used as an example of the treatment’s e¡ect.For some reason this issue is seen to be a particular
problem with meta-analyses. The pejorative phrase
‘‘combining apples and oranges’’ is often used in the con-
textof such analyses, butrarely when the original clinical
trial is considered, even though the inclusion criteria for
the latter are usually wide. It is often implied that meta-
analysis hides important treatment e¡ects by averaging,
whilst it is forgotten that a clinical trial can have exactly
the same e¡ect.Figure1illustrates di¡erentways of illus-
trating the distribution statistics around the mean im-
provement in FEV1in patients treatedwith a long-acting
beta2-agonist for COPD (8).The di¡erence between the
maximum and minimum actually measured is much
greater than one would imagine from looking at the
standard deviation or the standard error.
Two main factors lie behind these concerns about the
possibility that meta-analysis may hide a group of ‘good’
responders. One is the recognition that clinicians treat
individuals notgroups ofpatients or even the‘average’ pa-
tient.The second is the belief that a cherished treatment
works well in some patients. Of course it does, Fig. 1
shows that somepatients have an apparently large e¡ect
(which, of course includes a true biological e¡ect, spon-
taneous variation and measurement error). Such big ef-
fects stick in the mind of clinicians, not unreasonably.
Figure 1 also shows some quite large negative e¡ects,
but unless these are positively harmful, the clinician will
ignore these in practice and just conclude that the treat-
ment did not work in that particular individual.
Itwouldbe inappropriate to leave this sectionwithout
a further word about meta-analysis. This approach has
two main purposes. First, it can provide an average esti-
mate of the e⁄cacy of a treatment across a number of
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power of the analysis by combining results frommultiple
small trials.This illustrated by themeta-analysis in Fig. 2,
which shows that two trials of written self-management
plans coupledwith regular clinician review showed a sta-
tistically signi¢cant e¡ect, whilst two did not (9).Taking
the results from all four trials overall, there is a signi¢-
cant e¡ect. It would also be appropriate to warn that
meta-analysis can also under-estimate the level of statis-
tical signi¢cance from an individual trial’s results. In its
most widely used form, a meta-analysis is related to the
simpleunpaired t-test, butweighted to take into account
the size of the study and the amount of variation around
themeanresult.Theunpaired test is aweaker test than a
paired test because it contains both the variation within
a patient (i.e. the treatment e¡ect) and baseline varia-
tionsbetweenpatients.Thesebaseline di¡erences are ef-
fectively ‘noise’ if one is only interested in the change
with treatment. Paired analyses can remove the e¡ects
of between-patient di¡erences. A similar e¡ect can be
achieved by using di¡erences in change from baseline in
the two groups as the outcome measure in the meta-
analysis, rather than the di¡erence between the two
treatments groups at the end of the study.Modern clini-
cal trials often use a more sophisticated form of paired
analysis termed analysis of covariance. This can remove
even more of the baseline di¡erences between the pa-
tients and strengthen the statistical signi¢cance of the
treatment e¡ect.Unfortunately, it is not always possible
to replicate this sophisticated analysis when the re-
ported data from the trial are incorporated into a
meta-analysis. This can be confusing and lead to loss of
con¢dence in the meta-analysis since the trial, when
analysed in a meta-analysis, may appear to be not statis-
tically signi¢cant whereas it was when reported in theIgnacio-Garcia
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FIG. 2. Meta-analysis of four trials of the e¡ect of written self-
management plans plus regular clinician review vs. usual care on
hospital admissions in patients with asthma.The intervals show
the 95% con¢dence intervals.The arrow fordata fromthe study
of Ignacio-Garcia indicate that the mean and the lower con¢-
dence interval lie o¡ to the left-hand edge of the graph.Peto OR
indicates the Peto oddsratio (from Ref. (9)).primary paper.There are ways around this problem, but
only if the primary trialists report the ‘adjusted’ means
and standard deviations.
IDENTIFYINGPOTENTIAL
‘RESPONDERS’
Average treatment e¡ects, whether from a clinical trial
ormeta-analysis canprovide only the startingpoint for a
treatmentdecision. It is an interestingphenomenon, that
immediately on hearing the average result from a study,
most clinicians want to know in whom the treatment
works best or least. Unfortunately this type of
<?tf=62#post hoc analysis is open to many challenges,
not least the risk of chance ¢ndings resulting frommulti-
ple analyses of the same data set. The more post hoc
analyses that are undertaken, the greater the likelihood
of a ‘chance’ e¡ect being mistakenly taken for a ‘real’
e¡ect.
Itmaybepossible to pickup clues to the existence of a
subpopulation of patients who respond more than
others. This is illustrated in Fig. 3. Panel (A) shows the
most usual result from a large trialFa meanwith a nor-
mal distribution of data around it.The ‘good responders’
are clearly just the tail of the distribution and not sepa-
rate from the rest of the population. Panel (B) shows a
bimodal pattern of distribution in the results which
would provide very strong evidence for the existence of
a subgroup of responders.This is extremely rare, if it oc-
curs at all. In practice, the strongest hint for such pa-
tients may lie in a skewed distribution in which there is
an extended ‘tail’ of patients who have an apparently
large response (Panel C), however even this has to be in-
terpretedwith caution.
As pointed out above, enthusiasts who search for ‘re-
sponders’ ignore the ‘deterioraters’. A big response is
most likely to be just one that lies in the tail of the nor-
mal distribution that lies around anymeane¡ect.Post hoc
analyses of this type are justi¢able, however, if donewith
care.Many developments inmedicine have resulted from
serendipitous chance observations. In the context of a
clinical trial results, patterns in the results that suggest
‘good’ or ‘poor’ responders are hypothesis-generating,
and will depend on the identi¢cation of features that
characterise suchpatientsbefore they are given the treat-
ment.Once this can be done, thewhole picture changes
because subgroup analysis then become possible.
SUBGROUPANALYSES
Themost important aspect of a subgroup analysis is that
it is pre-speci¢ed and based upon a biologically plausible
di¡erence between patients. For example, children may
respond di¡erently to adults; or COPD patients with a
poor response to short-acting bronchodilatorsmay have
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FIG. 3. Simulated frequencydistribution show threetheoreti-
cal scenarios.OntheX-axis of eachis the improvement following
treatment. In Panel (A) is a normal distribution. In Panel (B) is a
bimodal distribution that suggests a subpopulation of patients
that show a larger response to treatment than the main group.
Panel (C) shows a skeweddistributioninwhichthere is a longtail
showinga smallnumberofpatientswithamuchbigger thanaver-
ageresponse.Thismight suggestthepresenceof agroupof ‘good
responders’, but other reasons for this pattern should also be
sought aswell.
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FIG. 4. Meta-analysisofe¡ectonhospital admissionofintrave-
nousmagnesiumgiventopatientswith acute asthma.The studies
have been grouped into patients with severe and those with
mild^moderate acute exacerbations. The intervals show the
95% con¢dence intervals.N = no. of patients in that arm of the
study; n = no. of patients admitted to hospital.Peto ORindicates
the Peto odds ratio (from Ref. (10)).
102 RESPIRATORYMEDICINEa similarly weak response to longer acting agents. A
good example of subgroup analysis is shown in the
meta-analysis in Fig. 4, in which it appears that patients
with less severe acute exacerbations of asthma appeared
not to respond to intravenous magnesium, whereas
more severe patients did (10).This is not the place to dis-
cuss possible mechanisms, but this analysis illustrates an
example of hypothesis generation and subgroup analysis
thatwould never havebeen possible if the authors of the
review had not attempted to aggregate all the data to-
gether into a meta-analysis.When the analysis was ¢rst
carried out, without subgroups, a signi¢cant amount of
di¡erence (or heterogeneity )was foundin the size of the
treatment e¡ect between the di¡erent studies. When
this was seen, the authors hypothesised that it could be
due to di¡erences in severity so theycarriedout this sub-
group analysis. The result should be thought of as being
hypothesis generating, rather than clear evidence that
patients with less severe attacks of asthma do not needmagnesium. However, the admission rate in the control
patients in the less severe group was lower than in the
more severe, lending support to the hypothesis and en-
couraging the design of trials to test this.
SUMMARY
Systematic reviews bring together and summarise in one
place, all the available evidence for a treatment’s e⁄cacy.
They should give the reader enough evidencewithwhich
to judge the reviewer’s interpretation of the data and the
implications for clinical practice. Meta-analysis can iden-
tify treatment e¡ects that may be missed by inadequate
trial size and occasionally can generate hypotheses con-
cerning patients whomay ormay not bene¢t from treat-
ment. The identi¢cation of ‘responders’ is not often
possible and we are usually left with the ‘on average’ re-
sult. This is perhaps the most important point of evi-
dence-based medicineFit provides the starting point
for intelligent and thoughtful practice, it is not a
straight-jacket of rigid rules.
REFERENCES
1. Dickersin K, Min YI, Meinert LL. Factors influencing publication of
research: follow up of applications to two institutional review
boards. JAMA 1997; 263: 374–378.
SYSTEMATICREVIEWS INRESPIRATORYMEDICINE 1032. Egger M, Zellweger-Za¨hner T, Schneider M, Junker C, Lengeler C,
Antes G. Language bias in randomised controoled trials published
in English and German. Lancet 1997; 350: 326–329.
3. Counsel C. Formulating questions and locating primary studies for
inclusion in syetmatic reviews. Ann Intern Med 1997; 127:
380–387.
4. Light RJ, Pillemer DB. Organising a review strategy. In: Light RJ
(ed.), SummingUp:The Science of Reviewing Reserach. Cambridge, M:
Harvard University Press; 1984: 13–31.
5. Nelson HS. Beta-adrenergic bronchodilators. N Eng. J Med 1995;
333: 499–506.
6. Cates CJ, Rowe BH, Bara A. Holding chamber versus nebulisers
for beta-agonist treatment of acute asthma (Cochrane Review). In:
The Cochrane Library, Issue 2 Oxford: Update Software, 2002.
7. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hird SS.
Global strategy for the diagnosis, management and prevention ofchronic obstructive pulmonary disease. NHLBI/WHO
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Workshop summary. Am J Resp Crit Care Med 2001; 163:
1256–1276.
8. Jones PW, Bosh TK. Changes in quality of life in COPD patients
treated with salmeterol. Am J Resp Crit Care Med 1997; 155:
1283–1289.
9. Gibson PG, Coughlan L, Wilson AJ, Abramson M, Bauman
A, Hensley MJ, Walters EH. Self-management education and
regular practitioner review for adults with asthma (Cochrane
Review). In: TheCochraneLibrary, Issue 2 Oxford: Update Software,
2002.
10. Rowe BH, Bretziaff JA, Bourdon C, Bota GW, Camargo CA.
Magnesium sulfate for treating exacerbations of acute asthma in
the emergency department (Cochrane Review). In: The Cochrane
Library, Issue 2 Oxford: Update Software, 2002.
